These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37979306)

  • 21. Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
    Barbe R; Belkouchi Y; Menu Y; Cohen R; David C; Kind M; Harguem S; Dawi L; Hadchiti J; Selhane F; Billet N; Ammari S; Bertin A; Lawrance L; Cervantes B; Hollebecque A; Balleyguier C; Cournede PH; Talbot H; Lassau N; Andre T
    Eur J Cancer; 2024 May; 202():114020. PubMed ID: 38502988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment.
    Hong JH; Woo IS
    Cancer Lett; 2023 Jul; 565():216236. PubMed ID: 37209943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future.
    Sahin IH; Zhang J; Saridogan T; Gorantla V; Rhree J; Malhotra M; Thomas R; Hsu D; Saeed A
    JCO Oncol Pract; 2023 May; 19(5):251-259. PubMed ID: 36862965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced Colorectal Carcinomas.
    Saberzadeh-Ardestani B; Graham RP; McMahon S; Ahanonu E; Shi Q; Williams C; Hubbard A; Zhang W; Muranyi A; Yan D; Jin Z; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2023 Oct; 29(20):4268-4277. PubMed ID: 37566222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
    Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
    Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
    André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
    Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 28. Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer.
    Huang Q; Yu T; Li L; Zhang Q; Zhang S; Li B; Li X; Xiao W; Liu G
    Appl Immunohistochem Mol Morphol; 2023 Feb; 31(2):84-93. PubMed ID: 36409630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of
    de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
    Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
    Colle R; Lonardi S; Cachanado M; Overman MJ; Elez E; Fakih M; Corti F; Jayachandran P; Svrcek M; Dardenne A; Cervantes B; Duval A; Cohen R; Pietrantonio F; André T
    Oncologist; 2023 Sep; 28(9):771-779. PubMed ID: 37023721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
    J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
    Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F
    Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
    Wu Q; Wang Z; Luo Y; Xie X
    BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.
    Han K; Tang JH; Liao LE; Jiang W; Sui QQ; Xiao BY; Li WR; Hong ZG; Li Y; Kong LH; Li DD; Zhang XS; Pan ZZ; Steele SR; Ding PR
    Dis Colon Rectum; 2023 Oct; 66(10):e996-e1005. PubMed ID: 35485833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.
    Gallois C; Landi M; Taieb J; Sroussi M; Saberzadeh-Ardestani B; Cazelles A; Lonardi S; Bergamo F; Intini R; Maddalena G; Pietrantonio F; Corti F; Ambrosini M; Martinetti A; Germani MM; Boccaccio C; Vetere G; Mouillet-Richard S; de Reynies A; Sinicrope FA; Cremolini C; Laurent-Puig P
    Clin Cancer Res; 2023 Sep; 29(18):3771-3778. PubMed ID: 37439810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
    Alouani E; Mercier M; Flecchia C; Auclin E; Hollebecque A; Mazard T; Turpin A; Pernot S; Cohen R; Dutherage M; Kim S; Sclafani F; Ben-Abdelghani M; Herve C; Aparicio T; De La Fouchardière C; Perkins G; Hautefeuille V; Jaffrelot M; Gallois C; Bongard V; Tougeron D; Taïeb J; Guimbaud R
    ESMO Open; 2023 Jun; 8(3):101574. PubMed ID: 37244250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
    Segal NH; Cercek A; Ku G; Wu AJ; Rimner A; Khalil DN; Reidy-Lagunes D; Cuaron J; Yang TJ; Weiser MR; Romesser PB; Stadler ZK; Varghese AM; Ganesh K; Yaeger R; Connell LC; Faleck D; Abou-Alfa GK; Mcauliffe KC; Vaiskauskas P; Solter ML; Ogle M; Adamow MJ; Holland A; Vedantam P; Wong P; Merghoub T; Vakiani E; Hollmann TJ; Juluru K; Chou JF; Capanu M; Erinjeri J; Solomon S; Yamada Y; Kemeny N; Crane CH; Saltz LB
    Clin Cancer Res; 2021 Apr; 27(8):2200-2208. PubMed ID: 33504552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration.
    Barraud S; Tougeron D; Villeneuve L; Eveno C; Bayle A; Parc Y; Pocard M; André T; Cohen R
    Dig Liver Dis; 2023 May; 55(5):673-678. PubMed ID: 36266207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.
    Yang K; Han L; Wu S; Qu X; Li Q; Zhao C; Zhou J; Jin X; Wang Y; Yan D; Cheng Z; Hua Y; Zhang Y; Ge Y; Sun J; Deng W; Zhao L; Zhao Y
    Cancer Immunol Immunother; 2022 Jun; 71(6):1443-1451. PubMed ID: 34689233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.